| Value | ₹52.75 Cr |
|---|
BSE filing, NSE: AKUMS. Summary written from the filing by ALFA Finder's alert engine.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹717.95
- Market cap
- ₹11,300 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 38.7×Sector 46.5×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Board Meeting Date
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing notes the removal of two entities from the promoter group.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
Akums Drugs & Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2025, in compliance with SEBI LODR regulations.
Other legal & regulatory announcements
All →Pervasive Commodities Legal & Regulatory
BSE waived Rs.11.07 lakh in fines levied on Pervasive Commodities for board and committee composition non-compliance. The company now owes no fine, so the monetary impact is nil.
- Value
- ₹0.11 Cr
Cummins India Legal & Regulatory
Cummins India received a CGST order from the Jaipur Commissionerate demanding Rs 5.19 Crore IGST plus an equal penalty for FY2020-21 to 2023-24. The company is evaluating an appeal, and the impact is not yet quantified.
- Value
- ₹5.19 Cr
Accelya Solutions India Legal & Regulatory
Accelya received an EPFO order to deposit Rs. 2.73 Crore in provident fund dues. The company may appeal, saying its records were not duly considered.
- Value
- ₹2.73 Cr
Engineers India Legal & Regulatory
Engineers India's Board noted NSE and BSE fines totalling Rs.10,73,800 for Regulation 17(1) non-compliance. Waiver is sought; the government must appoint the missing independent directors.
- Value
- ₹0.11 Cr
Engineers India Legal & Regulatory
Engineers India Limited has commented on exchange fines of Rs.5,36,900 each from NSE and BSE for Regulation 17(1) non-compliance on board independent directors for the quarter ended June 30, 2026. The company has sought waiver, noting the shortfall is beyond its control.
- Value
- ₹1.07 Cr
Sanco Trans Legal & Regulatory
Sanco Trans received a Customs order from the Trichy Commissioner for Rs. 15.98 Lakhs recovery, interest and penalty over alleged wrong duty drawback. The company is contesting it before appropriate legal forums.
- Value
- ₹0.16 Cr